Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV

Hepatology

Volumn 64, Issue 5, 2016, Pages 1818-1819

  Toyoda, Hidenori ^a   Kumada, Takashi ^a   Tada, Toshifumi ^a  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON;

AGE; ANTIVIRAL THERAPY; CANCER INCIDENCE; DRUG EFFICACY; HEPATITIS C; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; VIRAL CLEARANCE; INCIDENCE; LIVER TUMOR;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS C; HUMANS; INCIDENCE; LIVER NEOPLASMS;

EID: 84978525751     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28632     Document Type: Letter

References (3)

1. El-Serag HB, Kanwal F, Richardson P, DeBakey ME. Risk of hepatocellular carcinoma after sustained virologic response in veterans with HCV-infection. Hepatology 2016;64:130-137.
2. Iwasaki Y, Takaguchi K, Ikeda H, Makino Y, Araki Y, Ando M, et al. Risk factors for hepatocellular carcinoma in hepatitis C patients with sustained virologic response to interferon therapy. Liver Int 2004;24:603-610.
3. Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004;101:1616-1622.